Telix Pharmaceuticals (NASDAQ:TLX) Reaches New 12-Month Low – Here’s Why

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) reached a new 52-week low on Thursday . The stock traded as low as $8.83 and last traded at $8.83, with a volume of 41800 shares traded. The stock had previously closed at $9.04.

Wall Street Analysts Forecast Growth

TLX has been the topic of a number of recent analyst reports. Canaccord Genuity Group raised Telix Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 6th. Citigroup initiated coverage on Telix Pharmaceuticals in a research note on Thursday, September 18th. They issued a “buy” rating and a $22.00 price target on the stock. HC Wainwright cut their price target on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, September 10th. UBS Group lowered their price objective on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, September 23rd. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Telix Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Stock Down 2.6%

The company’s fifty day moving average is $10.09 and its 200 day moving average is $13.05.

Institutional Trading of Telix Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of TLX. Pier Capital LLC bought a new position in shares of Telix Pharmaceuticals during the second quarter valued at approximately $3,037,000. Blair William & Co. IL bought a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth approximately $217,000. Private Advisor Group LLC purchased a new stake in shares of Telix Pharmaceuticals in the 1st quarter worth approximately $170,000. ABC Arbitrage SA bought a new position in Telix Pharmaceuticals during the 1st quarter valued at approximately $451,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in Telix Pharmaceuticals during the second quarter valued at $297,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.